The Significance of Preoperative Chemotherapy in Evaluation of Recurrent Soft Tissue Liposarcoma Necrosis

Abstract

To investigate the effect of preoperative induction chemotherapy on treatment of recurrent liposarcoma. 21 patients with recurrent liposarcoma received the treatment of preoperative intra-arterial chemotherapy and surgical resection. Intra-arterial chemotherapy was given by subcutaneous implantable drug delivery system with infusion of cisplatin and doxorubicin followed by caffeine. After treatment, patients were followed up for 39 months. The liposarcoma changes in CT imaging were observed in 18 cases and there were 15 cases with medium or severe pathological changes caused by chemotherapy. At the end of the postoperative follow-up of 39 months, liposarcoma reoccurred locally in 2 cases; pulmonary metastasis occurred in 1 case and death in 3 cases. Preoperative intra-arterial chemotherapy is effective for highly malignant tumors such as recurrent liposarcoma and the judgment of prognosis is based on the postoperative pathological changes of such tumor.

Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma

“…Some retrospective analysis shows nearly all patients are treated with surgery, and more studies use adjuvant radiotherapy than chemotherapy (Ngan et al, 2013;Yetisyigit et al, 2013). In an effort to complement surgery, with inherent limitations of resection and high recurrence and the canceration rate of LPS, the administration of other treatment modalities, such as radiation therapy and chemotherapy, has been tried (Cui et al, 2012;Gronchi et al, 2014). Radiotherapy proved to benefit local control and CT showed a potential impact on the outcome of high-risk extremity LPS.…”

Combination of Western Medicine and Traditional Chinese Medicine for Treatment of Malignant Bone and Soft Tissue Tumors

“…Mortality, however, is high; the average fiveyear survival rate is only 60% [3]. Before the introduction of (neo-) adjuvant chemotherapy in the late 1970s, the long-term cure rate of non-metastatic osteosarcoma was 10-25% [4]. In recent years, advantages of neoadjuvant chemotherapy, which are suggested by Rosen, has been questioned and challenged by some scholars [5,6].…”